NCT04467723

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

Conditions

• NSCLC Stage IV
• NSCLC, Recurrent

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30

Timeline

• Start date: 2022-05-18
• Primary completion: 2027-01-01
• Completion: 2027-08-01
• First posted: 2020-07-13
• Last updated: 2026-01-28

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study